Search results
Showing 631 to 645 of 1331 results for heart OR cardi* OR arrythmia
NICE has developed a medtech innovation briefing (MIB) on End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia .
In development Reference number: GID-TA11352 Expected publication date: TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development Reference number: GID-TA10555 Expected publication date: TBC
This indicator covers the percentage of patients with coronary heart disease (CHD) who have had influenza immunisation in the preceding 1 August to 31 March. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM87
What is the utility of routine cardiovascular evaluation for asymptomatic people with FH?
Recommendation ID CG71/6 Question What is the utility of routine cardiovascular evaluation for asymptomatic people with FH? Any...
We have moved interventional procedures guidance 807 to become HealthTech guidance 764. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
include feeling very anxious. You might start shaking or sweating, your heart might beat faster and harder, and you might feel sick. You...
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).
This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.
View quality statements for QS204Show all sections
This quality standard covers managing acute painful episodes of sickle cell disease in hospital. It includes pain relief and care for children, young people and adults, from presentation in hospital until discharge. It describes high-quality care in priority areas for improvement.
View quality statements for QS58Show all sections
Sections for QS58
- Quality statements
- Quality statement 1: Timely assessment and analgesia
- Quality statement 2: Regular assessment of pain relief
- Quality statement 3: Strong opioids and monitoring
- Quality statement 4: Acute complications
- Quality statement 5: Protocols and specialist support
- Quality statement 6: Discharge information
- Update information
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
Discontinued Reference number: GID-MT557
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.